Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer

Surgery (United States)

Volumn 152, Issue 6, 2012, Pages 1078-1087

  Sosa, Julie A ^a   Balkissoon, Jai ^b   Lu, Shiao Ping ^b   Langecker, Peter ^b   Elisei, Rossella ^c   Jarzab, Barbara ^d   Bal, C S ^e   Marur, Shanthi ^f   Gramza, Ann ^g   Ondrey, Frank ^h  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Oxigene   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; PACLITAXEL;

ADULT; AGED; ANAPLASTIC THYROID CANCER; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; STILBENES; SURVIVAL RATE; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 84869399605     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.08.036     Document Type: Article

References (23)

1. G. Nagaiah, A. Hossain, C.J. Mooney, J. Parmentier, and S. Remick Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment J Oncol 2011 2011 542358
2. E. Kebebew, F.S. Greenspan, O.H. Clark, K.A. Woeber, and A. McMillan Anaplastic thyroid carcinoma: treatment outcome and prognostic factors Cancer 103 2005 1330 1335
3. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, and A. Trotti AJCC cancer staging manual 7th ed. 2009 Springer New York
4. O. Derbel, S. Limem, J.C. Segura-Ferlay, C. Carrier, J.L. Peix, and F. Borson-Chazot Results of combined treatment of anaplastic thyroid carcinoma (ATC) BMC Cancer 11 2011 469
5. R. De Crevoisier, E. Baudin, A. Bachelot, S. Leboulleux, J.-P. Travagli, and B. Caillou Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy Int J Radiat Oncol Biol Phys 60 2004 1137 1143
6. B. McIver, I.D. Hay, D.F. Giuffrida, C.E. Dvorak, C.S. Grant, and G.B. Thompason Anaplastic thyroid carcinoma: a 50-year experience at a single institution Surgery 130 2001 1028 1034
7. A.R. Shaha Airway management in anaplastic thyroid carcinoma Laryngoscope 118 2008 1195 1198
8. A.A. El-Zayat, D. Degen, S. Drabek, G.M. Clark, G.R. Pettit, and D.D. Von Hoff In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub) Anticancer Drugs 4 1993 19 25
9. G.G. Dark, S.A. Hill, V.E. Prise, G.M. Tozer, G.R. Pettit, and D.J. Chaplin Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Res 57 1997 1829 1834
10. L. Vincent, P. Kermani, L.M. Young, J. Cheng, F. Zhang, and K. Shido Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling J Clin Invest 115 2005 2992 3006
11. S.C. Yeung, M. She, H. Yang, J. Pan, L. Sun, and D. Chaplin Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model J Clin Endocrinol Metab 92 2007 2902 2909
12. A. Dowlati, K. Robertson, M. Cooney, W.P. Petros, M. Stratford, and J. Jesberger A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer Cancer Res 62 2002 3408 3416
13. C.J. Mooney, G. Nagaiah, P. Fu, J.K. Wasman, M.M. Cooney, and P.S. Savvides A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome Thyroid 19 2009 233 240
14. J.A. Sosa, R. Elisei, B. Jarzab, C.S. Bal, H. Koussis, and A.W. Gramza A randomized Phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial J Clin Oncol 2011 (29 Suppl):Abstract 5502
15. P.I. Haigh, P.H. Ituarte, H.S. Wu, P.A. Treseler, M.D. Posner, and J.M. Quivey Completely resected anaplastic carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival Cancer 91 2001 2335 2342
16. H.S. Chang, K.H. Nam, W.Y. Chung, and C.S. Park Anaplastic thyroid carcinoma: a therapeutic dilemma Yonsei Med J 46 2005 759 764
17. C. Are, and A.R. Shaha Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors and treatment approaches Ann Surg Oncol 13 2006 453 464
18. L.D. Green, L. Mack, and J.L. Pasieka Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies J Surg Oncol 94 2006 725 736
19. Y.S. Venkatesh, N.G. Ordonez, P.N. Schultz, R.C. Hickey, H. Goepfert, and N.A. Samaan Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases Cancer 66 1990 321 330
20. P.I. Haigh Anaplastic thyroid carcinoma Curr Treat Options Oncol 1 2000 353 357
21. J.D. Brierley Update on external beam radiation therapy in thyroid cancer J Clin Endocrinol Metab 96 2011 2289 2295
22. R.L. Neff, W.B. Farrar, and R.T. Kloos Anaplastic thyroid cancer Endocrinol Metab Clin North Am 37 2008 525 538
23. Y. Kitamura, K. Shimizu, M. Nagahama, K. Sugino, O. Ozaki, and T. Mimura Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases J Clin Endocrinol Metab 84 1999 4043 4049